Matt Labenski

Attending the @AcsMedi @EuroMedChem Medicinal Chemistry Frontiers meeting next week? Join us for Justin Rettenmaier’s presentation on the power of our RAPID chemoproteomics platform to discover medicines for challenging-to-drug targets @ 2pm 6/13: ow.ly/CPhZ50OK9Pp #medchem

Attending @CHI_Healthtech’s #DrugDiscoveryChemistry Conference? Stop by our presentation to learn how we’re leveraging our RAPID #chemoproteomics platform to discover novel small molecule medicines that unlock undruggable targets. View the agenda ow.ly/zVvR50NCkBL #biotech

We are incredibly excited to welcome so many wonderful new team members to Jnana. Interested in being a part of a team advancing treatment options for the most challenging targets and diseases? Check out our latest job openings: ow.ly/oblL50NuKQ7 #biotechjobs

Are you at the #NPKUA conference today? Don't miss Dr. Andreu Viader’s poster presentation on our potential first-in-class oral approach for the treatment of #PKU. #ChallengingPKU2022 #phenylketonuria

Outstanding review by Juswinder Singh. The Ascension of Targeted Covalent Inhibitors pubs.acs.org/doi/10.1021/ac…

To celebrate outstanding leaders in the biotech industry for #WomensHistoryMonth, today we recognize Joanne Kotz, co-founder and CEO of Jnana Therapeutics, which uses its next-generation chemoproteomic platform to address well-validated but hard-to-drug targets

Today, we recognize people around the world with rare diseases. We are advancing JNT-517 as development candidate and potential first-in-class oral treatment for #PKU.

A human biology-based drug discovery effort coupled with a powerful binder-based chemoproteomics Platform is paving a path for PKU patients @jnanatx. And structure-guided optimization reveals the novel solutions that arise. Bravo @jcbarrish and team.

Excited to announce we are advancing JNT-517 as a Development Candidate and potential first-in-class oral treatment for PKU bit.ly/3BHRwF8

Jnana CEO, @JoanneKotz, will be presenting at #JPM22 on our next gen chemoproteomic platform to pursue hard-to-drug targets. Learn more here: bit.ly/3zuatdo

We’re applying our RAPID platform to address hard-to-drug targets including SLC transporters, scaffold proteins, transcription factors, phosphatases, and helicases. ow.ly/g9PM50GE9Hk

Peters’ alternative to HR3 represents progress in debate on needed healthcare reforms. Everyone in biotech, please read. ⁦@ScottPetersSD⁩ —- “Opinion: As a House member, here's why I can't support the Lower Drug Costs Now Act” sandiegouniontribune.com/opinion/commen…

Smashing work from @LabenskiMatt Leslie pubs.acs.org/doi/10.1021/ac…

@LynJonesChemBio Thanks, Lyn!

Our next generation chemoproteomic RAPID platform enables us to address well-validated but hard-to-drug targets, including the solute carrier (SLC) family of metabolite transporters and beyond. jnanatx.com/platform/

Our lead program is designed to provide a novel oral approach to address #PKU by inhibiting the SLC transporter SLC6A19 that is responsible for kidney reabsorption of phenylalanine. jnanatx.com/pipeline/

Jnana closes $50M series B round, picks PKU as lead indication bioworld.com/articles/51057…

This financing funds progression of our lead program, an oral approach to treating phenylketonuria (#PKU), into the clinic and supports expanded application of our chemoproteomic RAPID platform for small-molecule discovery for hard-to-drug targets. ow.ly/Pdo450FTtSU

Fierce Biotech digs into our Series B news today: ow.ly/lx2g50FTG3C